FreeTheAI

Galderma Expands Skincare Portfolio with $1.5 Billion Acquisition of ZO Skin Health

BullishMedium impact
GALDCHF 167.35 −0.48%BX$109.98 −4.18%

Dermatology firm Galderma Group AG (SIX:GALD) has reached a deal to buy ZO Skin Health in an all-cash transaction valued at $1.5 billion. The seller group includes funds managed by private equity firm Blackstone Inc. (NYSE:BX) as well as members of the Obagi family. Galderma intends to finance the purchase using available cash reserves alongside new bank debt.

Headquartered in California, ZO Skin Health specializes in clinical skincare products prescribed by healthcare professionals. Over the year ending June 2026, the company generated around $330 million in revenue. Its lineup of more than 40 daily care items reaches clients through approximately 16,500 medical practices, aesthetic spas, and digital storefronts in over 40 nations. The acquisition complements Galderma's existing brands, such as Cetaphil and Alastin, by adding protocol-based retinol and acid treatments.

Completion of the buyout is projected for late 2026 or early 2027, pending standard regulatory reviews. Management expects the purchase to have no impact on Core EPS during its initial full year under new ownership. While margins may experience a minor squeeze in 2027 due to stepped-up commercial marketing, profitability should realign with Galderma's overall average starting in 2028.

Key points

  • Galderma Group AG is buying ZO Skin Health in an all-cash deal with an enterprise valuation of $1.5 billion.
  • The target company recorded roughly $330 million in sales over the 12-month window through June 2026.
  • Financing will come from Galderma's existing cash balances combined with borrowing from banks.
  • The acquisition is targeted to finish between late 2026 and early 2027, subject to official approval.
  • Earnings per share are anticipated to remain neutral in year one, with margins recovering by 2028.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the purchase price for ZO Skin Health?

Galderma is paying $1.5 billion in cash to acquire ZO Skin Health, relying on corporate cash reserves and bank loans.

When will Galderma finalize the buyout?

The transaction should complete in the final quarter of 2026 or early 2027, once regulatory agencies approve the deal.

How will the purchase affect Galderma's financial metrics?

The deal will not affect Core EPS in its first full year and is projected to match standard group profit margins by 2028.